These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 21053952)
1. Effects of charge on antibody tissue distribution and pharmacokinetics. Boswell CA; Tesar DB; Mukhyala K; Theil FP; Fielder PJ; Khawli LA Bioconjug Chem; 2010 Dec; 21(12):2153-63. PubMed ID: 21053952 [TBL] [Abstract][Full Text] [Related]
2. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715 [TBL] [Abstract][Full Text] [Related]
3. Membrane association, electrostatic sequestration, and cytotoxicity of Gly-Leu-rich peptide orthologs with differing functions. Vanhoye D; Bruston F; El Amri S; Ladram A; Amiche M; Nicolas P Biochemistry; 2004 Jul; 43(26):8391-409. PubMed ID: 15222751 [TBL] [Abstract][Full Text] [Related]
4. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ MAbs; 2015; 7(3):483-93. PubMed ID: 25695748 [TBL] [Abstract][Full Text] [Related]
5. Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications. Iafisco M; Varoni E; Di Foggia M; Pietronave S; Fini M; Roveri N; Rimondini L; Prat M Colloids Surf B Biointerfaces; 2012 Feb; 90():1-7. PubMed ID: 22015181 [TBL] [Abstract][Full Text] [Related]
6. Targeted drug delivery using immunoconjugates: principles and applications. Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410 [TBL] [Abstract][Full Text] [Related]
7. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424 [TBL] [Abstract][Full Text] [Related]
15. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Quadri SM; Vriesendorp HM Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840 [TBL] [Abstract][Full Text] [Related]
16. Antibody engineering and modification technologies. Filpula D Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589 [TBL] [Abstract][Full Text] [Related]
17. Modulation of antibody pharmacokinetics by chemical polysialylation. Constantinou A; Epenetos AA; Hreczuk-Hirst D; Jain S; Deonarain MP Bioconjug Chem; 2008 Mar; 19(3):643-50. PubMed ID: 18307285 [TBL] [Abstract][Full Text] [Related]
18. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Graff CP; Wittrup KD Cancer Res; 2003 Mar; 63(6):1288-96. PubMed ID: 12649189 [TBL] [Abstract][Full Text] [Related]
19. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy. Ran Y; Hu H; Hu D; Zhou Z; Sun Y; Yu L; Sun L; Pan J; Liu J; Liu T; Yang Z Clin Cancer Res; 2008 Oct; 14(20):6538-45. PubMed ID: 18927294 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Levêque D; Wisniewski S; Jehl F Anticancer Res; 2005; 25(3c):2327-43. PubMed ID: 16080460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]